Globus Medical, Inc.

As of June 30, 2026, Globus Medical Inc Class A carries a market capitalization of 196.68B, placing it among publicly traded companies globally. Its enterprise value stands at 188.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Globus Medical Inc Class A's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Globus Medical Inc Class A has 134.25M shares outstanding.

As of June 30, 2026, Globus Medical Inc Class A trades at a trailing price-to-earnings ratio of 21.12. The price-to-sales ratio is 3.59, and the price-to-book ratio stands at 2.36.

As of June 30, 2026, Globus Medical Inc Class A trades at an EV/EBITDA multiple of 11.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.85 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Globus Medical Inc Class A trades at an EV/FCF ratio of 14.35, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 188.22B versus a market cap of 196.68B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Globus Medical Inc Class A maintains a current ratio of 4.62, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Globus Medical Inc Class A posted a return on equity (ROE) of 11.81, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.16 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.25, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.52, useful for judging operating efficiency across full business cycles. The company generates approximately 9.43M in revenue per employee across its workforce of 5,825.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.25 indicates how many times Globus Medical Inc Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Globus Medical Inc Class A recorded 2.18B in income tax expense. That works out to an effective tax rate of 18.89, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.53B, leaving 9.35B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 30, 2026, Globus Medical Inc Class A's stock has gained approximately 17.20% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Globus Medical Inc Class A generated 54.95B in revenue and converted that into 9.35B in net income, yielding earnings per share of 68.34. EBITDA reached 16.06B, while operating income came in at 11.77B.

As of June 30, 2026, Globus Medical Inc Class A holds 10.40B in cash and equivalents against 1.94B in total debt, resulting in a net debt position of -8.87B. Total book value stands at 83.32B, with working capital of 30.33B providing operational flexibility.

Globus Medical Inc Class A produced 15.91B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.79B in capital expenditures, free cash flow totaled 13.12B - equivalent to 97.29 per share.

Over the twelve months ended June 30, 2026, Globus Medical Inc Class A posted a gross margin of 68.55, reflecting its pricing power and cost economics. The operating margin of 21.42 and net profit margin of 17.03 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.54, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Globus Medical Inc Class A shareholders.

As of June 30, 2026, Globus Medical Inc Class A has an Altman Z-Score of 12.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.